For years, millions of Americans swallowed daily blood-pressure pills trusting they were safe. Then, in 2018, the U.S. Food and Drug Administration began discovering that tablets of Valsartan, Irbesartan, and Losartan from multiple manufacturers were contaminated with N-Nitrosodimethylamine (NDMA), a chemical the International Agency for Research on Cancer classifies as a Group 2A probable human carcinogen. The FDA estimated roughly two million patients had already been exposed by the time recalls began. Now a $200 million federal settlement offers those patients compensation, but the claims deadline is June 2, 2026, and it is not flexible.
How a cancer-linked chemical hid in plain sight
Valsartan, Irbesartan, and Losartan belong to a drug class called angiotensin II receptor blockers, or ARBs, prescribed widely for high blood pressure and heart failure. The contamination was not a single manufacturing error. A Washington Post investigation found that NDMA and related nitrosamine byproducts went undetected for years across overseas production facilities. Nitrosamines can damage DNA at the molecular level, which is why even low-level, long-term exposure raised alarms.
The FDA responded with a rolling series of recalls that eventually spanned dozens of product lines from multiple manufacturers and repackagers. The agency’s ARB recall page catalogs every affected product by manufacturer, drug strength, lot number, and National Drug Code (NDC). That NDC detail matters right now: to file a valid settlement claim, you need to confirm your specific prescription matches a recalled product on the FDA’s list.
Thousands of lawsuits became one federal case
Patients across the country sued, alleging that manufacturers failed to test for nitrosamine contamination and that pharmacies dispensed tainted pills without warning. Because so many cases raised overlapping facts, the Judicial Panel on Multidistrict Litigation consolidated them into a single proceeding: MDL No. 2875, in the U.S. District Court for the District of New Jersey. The defendants in the litigation include generic manufacturers such as Zhejiang Huahai Pharmaceutical, Hetero Labs, and several other companies whose facilities produced the contaminated active ingredient. Consolidation grouped thousands of individual claims under one judge, streamlining discovery and settlement talks instead of letting cases scatter across dozens of courts.
The resulting $200 million settlement covers patients who filled prescriptions for recalled lots of Valsartan, Irbesartan, or Losartan. The settlement figure has been reported in federal court filings associated with MDL No. 2875. Claims are being processed through the official settlement website at valsartanmdlsettlement.com, which serves as the portal managed by the court-appointed settlement administrator. As of late May 2026, the precise formula for distributing funds among claimants has not been published on federal agency websites. The settlement does not appear to require proof that a claimant developed cancer; rather, it is structured to compensate patients who filled prescriptions for recalled lots, though the payout formula may weigh factors such as duration of use and whether a subsequent cancer diagnosis occurred. Key open questions include exactly how the settlement distinguishes payout tiers and whether attorneys’ fees and administrative costs are deducted from the $200 million pool before individual amounts are calculated. What is firm: the deadline to submit a claim is June 2, 2026.
How to file a claim before the June 2 deadline
Filing requires a few concrete steps. Starting now leaves just enough time to gather what you need.
1. Pull your pharmacy records. Contact your pharmacy (or pharmacies, if you switched over the years) and request your full prescription history for Valsartan, Irbesartan, or Losartan. You need the drug name, manufacturer, NDC number, and the dates each prescription was filled. Most major chains can retrieve this electronically, even for prescriptions filled before 2019.
2. Cross-check against the FDA recall list. Go to the FDA’s ARB recall page and compare your NDC numbers to the recalled products. Not every version of these drugs was contaminated. Only prescriptions matching specific manufacturers, lot numbers, and NDC codes qualify.
3. Submit through the official settlement portal. File your claim at valsartanmdlsettlement.com before June 2, 2026. If you are working with an attorney or a consumer legal clinic, they can guide you through the submission. If you are filing on your own, have your pharmacy documentation ready and follow the step-by-step instructions on the site.
4. Report adverse effects separately. If you experienced serious side effects or were later diagnosed with cancer, consider filing an adverse-event report with the FDA through its online problem-reporting portal. This does not replace a settlement claim, but it feeds into the agency’s ongoing safety surveillance.
Questions the settlement leaves open
The legal process is winding down, yet significant scientific gaps persist. No published FDA analysis has quantified how many cancer cases are directly attributable to nitrosamine exposure from these ARB medications. Drawing that connection would require matching detailed prescription and dosage records against long-term health outcomes for millions of patients, and those datasets have not been made public. The FDA’s MedWatch system collects individual adverse-event reports, but voluntary reporting is not the same as a controlled epidemiological study.
The fallout also extends beyond this settlement. The ARB contamination crisis pushed the FDA to impose stricter nitrosamine testing requirements across the entire generic drug supply chain, not just for blood-pressure medications. Those reforms are still being phased in as of mid-2026, and their long-term effectiveness will determine how quickly future contamination is caught before patients are exposed.
How to act before the June 2, 2026 claims deadline closes
For the roughly two million patients the FDA estimates were exposed, the immediate question is not scientific but practical. If your pharmacy records show you filled a prescription for a recalled lot of Valsartan, Irbesartan, or Losartan, you have until June 2, 2026, to file through the official settlement portal. After that date, this window closes regardless of whether you participated. Pull your records, check the FDA’s list, and decide before the deadline passes.
